Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. During the ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab).